Monthly Archives: February 2023

• 

Genes reveal risk of recurrence of kidney cancer

By Sharon Deveson Kell|2023-02-27T10:37:25+00:0027 Feb 2023|Drug treatments|

Looking at a person's DNA using a technique called DNA [...]

Read More

Comments Off on Genes reveal risk of recurrence of kidney cancer

• 

Adjuvant nivolumab plus ipilimumab in localised kidney cancer

By Sharon Deveson Kell|2023-02-27T10:20:33+00:0027 Feb 2023|Drug treatments|

A recent phase 3 study called CheckMate 914 has shown [...]

Read More

Comments Off on Adjuvant nivolumab plus ipilimumab in localised kidney cancer

• 

Coalition for reducing bureaucracy in clinical trials

By Sharon Deveson Kell|2023-03-14T13:11:16+00:0024 Feb 2023|Patient advocacy|

In September 2020 a broad cross-disciplinary coalition of medical societies [...]

Read More

Comments Off on Coalition for reducing bureaucracy in clinical trials

• 

ASCO GU 2023: Further information from the cabozantinib plus nivolumab study

By Sharon Deveson Kell|2023-02-23T14:39:48+00:0023 Feb 2023|Drug treatments|

At the American Society of  Clinical Oncology Genitourinary Cancers Conference [...]

Read More

Comments Off on ASCO GU 2023: Further information from the cabozantinib plus nivolumab study

• 

It changed my life: Steve Pointon

By Sharon Deveson Kell|2023-02-23T14:16:29+00:0023 Feb 2023|Uncategorized|

In this article, Steve Pointon describes how counselling for kidney [...]

Read More

Comments Off on It changed my life: Steve Pointon

• 

ASCO GU 2023: Outcomes of patients with kidney cancer brain metastases treated with first-line therapies

By Sharon Deveson Kell|2023-02-22T09:46:42+00:0022 Feb 2023|Drug treatments|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: Outcomes of patients with kidney cancer brain metastases treated with first-line therapies

• 

ASCO GU 2023: Adjuvant pembrolizumab for different risks and stages of kidney cancer

By Sharon Deveson Kell|2023-02-22T09:34:55+00:0022 Feb 2023|Drug treatments|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: Adjuvant pembrolizumab for different risks and stages of kidney cancer

• 

ASCO GU 2023: Patient perception of benefits and risks of adjuvant therapy for kidney cancer

By Sharon Deveson Kell|2023-02-22T09:52:33+00:0022 Feb 2023|Drug treatments|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: Patient perception of benefits and risks of adjuvant therapy for kidney cancer

• 

ASCO GU 2023: How do patients around the world experience kidney cancer?

By Sharon Deveson Kell|2023-02-22T09:51:07+00:0022 Feb 2023|Cancer news|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: How do patients around the world experience kidney cancer?

• 

Cancer in the UK: Overview 2023

By Sharon Deveson Kell|2023-02-08T10:09:21+00:008 Feb 2023|Patient advocacy|

Cancer Research UK have written a report that sets out [...]

Read More

Comments Off on Cancer in the UK: Overview 2023